IDIOPATHIC PULMONARY FIBROSIS

This study looks at the long-term safety of a daily pill called nerandomilast for people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). About 1,700 adults who finished a previous nerandomilast study can join. They take the drug for up to 22 mont…

This study tests an experimental drug called SB17170 in 30 adults aged 40 and older with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. Participants will receive either the drug or a placebo for 12 weeks. The main goal is to see i…

This study tests a new medicine called BI 765423 in people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. About 71 adults aged 40 and older will receive either the drug or a placebo by IV every 4 weeks for 3 months. The main …

This study looks at whether adding the antibiotic azithromycin to usual treatment can shorten hospital stays for people with idiopathic pulmonary fibrosis (IPF) who are having a sudden flare-up. About 1000 adults with mild or early-moderate IPF will take part. Researchers will co…

This study tests if a lung transplant followed by a bone marrow transplant can help people with end-stage lung disease (like pulmonary fibrosis or COPD) who also have bone marrow failure. The goal is to first fix the lungs, then restore healthy blood cell production. The trial is…

This study tests whether adding intravenous immunoglobulin (IVIG) to standard care helps people hospitalized with sudden, severe worsening of idiopathic pulmonary fibrosis (IPF). About 196 adults with IPF and an acute exacerbation will receive either usual treatment alone or usua…

This study tests an experimental drug called ABBV-142 for people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and makes breathing hard. About 165 adults will receive either the drug or a placebo for 52 weeks to see if it safely slows lung fun…

This study tests an experimental oral drug called PIPE-791 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. About 324 adults aged 40 and older will receive either the drug or a placebo to see if it improves lung fu…

This early-stage study tests whether artesunate, a drug used for malaria, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. Fifteen adults aged 40 and older will receive either artesunate or a placebo for 12 w…

This study tests an oral drug called H01 (hymecromone) in 37 adults with interstitial lung disease, a condition that causes lung scarring and often leads to death within 3-5 years. Participants take the drug twice daily for 12 weeks. The goal is to see if H01 can lower a marker o…

This study tests whether an oral drug, ifetroban, can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 128 adults aged 40 and older with IPF will receive either ifetroban or a placebo for 52 weeks. The main goal…

This study tests whether lansoprazole, a drug that reduces stomach acid, can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and breathing problems. About 298 adults with IPF from UK hospitals will take either lansoprazole …

This study tests whether the experimental drug MTX-463 can help people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. About 164 adults aged 40 and older with IPF will receive either MTX-463 or a placebo for 24 weeks…

This study tests a drug called senicapoc to see if it can prevent lung scarring from getting worse in people with progressive fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 adults will take either senicapoc or a placebo for 26 weeks. Re…

This study tests whether taking zinc and nicotinamide riboside (a form of vitamin B3) twice a day for 24 weeks can improve symptoms and quality of life in people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. The trial is designed to be done mostly from home, w…

This early-stage study tests a drug called nalbuphine ER in 10 adults with idiopathic pulmonary fibrosis (IPF), a condition that scars the lungs and makes breathing hard. The goal is to see if the drug is safe and can improve breathing function. Participants will take increasing …

This study is testing a wearable device called C-mo System to see how well it can automatically detect and describe coughs in people with conditions like asthma, COPD, or chronic cough. About 300 participants aged 2 and older will wear the device for 24 hours and complete diaries…

This study aims to find genetic and protein markers that could predict when a person with idiopathic pulmonary fibrosis might experience a rapid decline in lung function. Researchers will compare these markers with changes in symptoms over time. The study enrolls 500 adults diagn…

This study looks at whether leg muscle issues contribute to shortness of breath and exercise problems in people with interstitial lung disease (ILD). Researchers will compare leg muscle structure and function in 40 ILD patients, and test if muscle fatigue limits exercise. They wi…

This early-stage study tests a new oral drug, GNS-3545, in 72 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a disease that causes lung scarring. Participants receive either the drug or a placebo, …

This study looks at how pirfenidone changes the amount of another medicine, BI 1015550, in the blood of adults with idiopathic pulmonary fibrosis (IPF). Twenty participants aged 40 and older will take both drugs over about a month, with frequent blood tests and clinic visits. The…

This study looks at whether people with idiopathic pulmonary fibrosis (IPF) have problems in their small airways before starting any medication. Researchers will use a simple breathing test called nitrogen washout to check for these issues. The goal is to understand how common sm…

This study is an early safety check for a new drug called SV001, which may one day treat idiopathic pulmonary fibrosis (a serious lung disease). It involves 53 healthy adults in China who will receive either a single dose of SV001 or a placebo. The main goal is to see if the drug…

This early-stage study tests the safety of a new drug called SRN001 in 30 healthy adult men of Korean or Caucasian background. Participants receive multiple doses of the drug or a placebo to check for side effects and how the drug moves through the body. The goal is to gather saf…

This study is creating a registry and biobank for people with interstitial lung diseases (ILD), including sarcoidosis and pulmonary fibrosis. Researchers will collect medical data and biological samples from up to 1,000 participants to support future studies. The goal is to bette…

This early-stage study looks at how the experimental drug ENV-101 interacts with two standard IPF medicines, nintedanib and pirfenidone, in healthy adults. Researchers will measure drug levels in the blood to understand safety and dosing. The study involves 57 participants across…

This study follows 750 close relatives of people with a rare, inherited form of lung scarring called familial pulmonary fibrosis. Participants have no symptoms yet but carry a higher genetic risk. Researchers will track their health over time with yearly surveys and in-person vis…